Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator

Li Ching Wu, Li Tzong Chen, Yueh Ju Tsai, Chun Mao Lin, Ching Yih Lin, Yu Fang Tian, Ming Juen Sheu, Yih Huei Uen, Yow Ling Shiue, Yu Hui Wang, Shu Jing Yang, Wen Ren Wu, Shau Hsuan Li, Masaya Iwamuro, Naoya Kobayasshi, Hsuan Ying Huang, Chien Feng Li

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims: Increased β-oxidation of branched-chain fatty acids provides an additional metabolic advantage for cancer cells thereby enhancing tumour development and progression. Alpha-methylacyl coenzyme A racemase (AMACR) is an enzyme essential for the catabolism of branched-chain fatty acids that allows their subsequent b-oxidation and thus plays an important role in generating biological energy. However, the expression of AMACR has never been systemically investigated in gallbladder carcinoma. This study evaluated the expression status, associations with clinicopathological variables and prognostic implications of AMACR in a well-defined cohort of gallbladder carcinoma and confirmed their expression status in gallbladder carcinoma cells. Methods: AMACR immunostaining was assessable in 89 cases on tissue microarrays of gallbladder carcinoma, and it was correlated with clinicopathological factors and patient survival. In three gallbladder carcinoma cell lines and one non-tumorigenic cholangiocyte, AMACR mRNA expression was measured by real-time reverse transcription PCR and the endogenous expression of AMACR protein was analysed by western blotting. Results: AMACR overexpression was significantly associated with an advanced primary tumour status (p=0.027) and American Joint Committee on Cancer stage (p=0.027), an increased histological grade (p=0.002) and vascular invasion (p=0.017). Importantly, AMACR overexpression independently predicted worse disease-specific survival (p=0.0452, RR 1.887). Expression levels of AMACR mRNA and total protein in various cells were comparable. The abundance of AMACR expression increased in tumour cells and was even higher in the metastatic cell line. Conclusions: In primary gallbladder carcinoma, AMACR overexpression was correlated with important prognosticators and independently portended worse outcomes, highlighting the potential prognostic and therapeutic utility of AMACR in gallbladder carcinoma.

Original languageEnglish
Pages (from-to)309-314
Number of pages6
JournalJournal of Clinical Pathology
Volume65
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Racemases and Epimerases
Coenzyme A
Gallbladder
Carcinoma
Neoplasms
Fatty Acids
Cell Line
Messenger RNA
Survival
Reverse Transcription
Blood Vessels
Proteins

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator. / Wu, Li Ching; Chen, Li Tzong; Tsai, Yueh Ju; Lin, Chun Mao; Lin, Ching Yih; Tian, Yu Fang; Sheu, Ming Juen; Uen, Yih Huei; Shiue, Yow Ling; Wang, Yu Hui; Yang, Shu Jing; Wu, Wen Ren; Li, Shau Hsuan; Iwamuro, Masaya; Kobayasshi, Naoya; Huang, Hsuan Ying; Li, Chien Feng.

In: Journal of Clinical Pathology, Vol. 65, No. 4, 04.2012, p. 309-314.

Research output: Contribution to journalArticle

Wu, LC, Chen, LT, Tsai, YJ, Lin, CM, Lin, CY, Tian, YF, Sheu, MJ, Uen, YH, Shiue, YL, Wang, YH, Yang, SJ, Wu, WR, Li, SH, Iwamuro, M, Kobayasshi, N, Huang, HY & Li, CF 2012, 'Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator', Journal of Clinical Pathology, vol. 65, no. 4, pp. 309-314. https://doi.org/10.1136/jclinpath-2011-200489
Wu, Li Ching ; Chen, Li Tzong ; Tsai, Yueh Ju ; Lin, Chun Mao ; Lin, Ching Yih ; Tian, Yu Fang ; Sheu, Ming Juen ; Uen, Yih Huei ; Shiue, Yow Ling ; Wang, Yu Hui ; Yang, Shu Jing ; Wu, Wen Ren ; Li, Shau Hsuan ; Iwamuro, Masaya ; Kobayasshi, Naoya ; Huang, Hsuan Ying ; Li, Chien Feng. / Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator. In: Journal of Clinical Pathology. 2012 ; Vol. 65, No. 4. pp. 309-314.
@article{a09edd6eb23a44fc97a9904710d2fd1f,
title = "Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator",
abstract = "Aims: Increased β-oxidation of branched-chain fatty acids provides an additional metabolic advantage for cancer cells thereby enhancing tumour development and progression. Alpha-methylacyl coenzyme A racemase (AMACR) is an enzyme essential for the catabolism of branched-chain fatty acids that allows their subsequent b-oxidation and thus plays an important role in generating biological energy. However, the expression of AMACR has never been systemically investigated in gallbladder carcinoma. This study evaluated the expression status, associations with clinicopathological variables and prognostic implications of AMACR in a well-defined cohort of gallbladder carcinoma and confirmed their expression status in gallbladder carcinoma cells. Methods: AMACR immunostaining was assessable in 89 cases on tissue microarrays of gallbladder carcinoma, and it was correlated with clinicopathological factors and patient survival. In three gallbladder carcinoma cell lines and one non-tumorigenic cholangiocyte, AMACR mRNA expression was measured by real-time reverse transcription PCR and the endogenous expression of AMACR protein was analysed by western blotting. Results: AMACR overexpression was significantly associated with an advanced primary tumour status (p=0.027) and American Joint Committee on Cancer stage (p=0.027), an increased histological grade (p=0.002) and vascular invasion (p=0.017). Importantly, AMACR overexpression independently predicted worse disease-specific survival (p=0.0452, RR 1.887). Expression levels of AMACR mRNA and total protein in various cells were comparable. The abundance of AMACR expression increased in tumour cells and was even higher in the metastatic cell line. Conclusions: In primary gallbladder carcinoma, AMACR overexpression was correlated with important prognosticators and independently portended worse outcomes, highlighting the potential prognostic and therapeutic utility of AMACR in gallbladder carcinoma.",
author = "Wu, {Li Ching} and Chen, {Li Tzong} and Tsai, {Yueh Ju} and Lin, {Chun Mao} and Lin, {Ching Yih} and Tian, {Yu Fang} and Sheu, {Ming Juen} and Uen, {Yih Huei} and Shiue, {Yow Ling} and Wang, {Yu Hui} and Yang, {Shu Jing} and Wu, {Wen Ren} and Li, {Shau Hsuan} and Masaya Iwamuro and Naoya Kobayasshi and Huang, {Hsuan Ying} and Li, {Chien Feng}",
year = "2012",
month = "4",
doi = "10.1136/jclinpath-2011-200489",
language = "English",
volume = "65",
pages = "309--314",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator

AU - Wu, Li Ching

AU - Chen, Li Tzong

AU - Tsai, Yueh Ju

AU - Lin, Chun Mao

AU - Lin, Ching Yih

AU - Tian, Yu Fang

AU - Sheu, Ming Juen

AU - Uen, Yih Huei

AU - Shiue, Yow Ling

AU - Wang, Yu Hui

AU - Yang, Shu Jing

AU - Wu, Wen Ren

AU - Li, Shau Hsuan

AU - Iwamuro, Masaya

AU - Kobayasshi, Naoya

AU - Huang, Hsuan Ying

AU - Li, Chien Feng

PY - 2012/4

Y1 - 2012/4

N2 - Aims: Increased β-oxidation of branched-chain fatty acids provides an additional metabolic advantage for cancer cells thereby enhancing tumour development and progression. Alpha-methylacyl coenzyme A racemase (AMACR) is an enzyme essential for the catabolism of branched-chain fatty acids that allows their subsequent b-oxidation and thus plays an important role in generating biological energy. However, the expression of AMACR has never been systemically investigated in gallbladder carcinoma. This study evaluated the expression status, associations with clinicopathological variables and prognostic implications of AMACR in a well-defined cohort of gallbladder carcinoma and confirmed their expression status in gallbladder carcinoma cells. Methods: AMACR immunostaining was assessable in 89 cases on tissue microarrays of gallbladder carcinoma, and it was correlated with clinicopathological factors and patient survival. In three gallbladder carcinoma cell lines and one non-tumorigenic cholangiocyte, AMACR mRNA expression was measured by real-time reverse transcription PCR and the endogenous expression of AMACR protein was analysed by western blotting. Results: AMACR overexpression was significantly associated with an advanced primary tumour status (p=0.027) and American Joint Committee on Cancer stage (p=0.027), an increased histological grade (p=0.002) and vascular invasion (p=0.017). Importantly, AMACR overexpression independently predicted worse disease-specific survival (p=0.0452, RR 1.887). Expression levels of AMACR mRNA and total protein in various cells were comparable. The abundance of AMACR expression increased in tumour cells and was even higher in the metastatic cell line. Conclusions: In primary gallbladder carcinoma, AMACR overexpression was correlated with important prognosticators and independently portended worse outcomes, highlighting the potential prognostic and therapeutic utility of AMACR in gallbladder carcinoma.

AB - Aims: Increased β-oxidation of branched-chain fatty acids provides an additional metabolic advantage for cancer cells thereby enhancing tumour development and progression. Alpha-methylacyl coenzyme A racemase (AMACR) is an enzyme essential for the catabolism of branched-chain fatty acids that allows their subsequent b-oxidation and thus plays an important role in generating biological energy. However, the expression of AMACR has never been systemically investigated in gallbladder carcinoma. This study evaluated the expression status, associations with clinicopathological variables and prognostic implications of AMACR in a well-defined cohort of gallbladder carcinoma and confirmed their expression status in gallbladder carcinoma cells. Methods: AMACR immunostaining was assessable in 89 cases on tissue microarrays of gallbladder carcinoma, and it was correlated with clinicopathological factors and patient survival. In three gallbladder carcinoma cell lines and one non-tumorigenic cholangiocyte, AMACR mRNA expression was measured by real-time reverse transcription PCR and the endogenous expression of AMACR protein was analysed by western blotting. Results: AMACR overexpression was significantly associated with an advanced primary tumour status (p=0.027) and American Joint Committee on Cancer stage (p=0.027), an increased histological grade (p=0.002) and vascular invasion (p=0.017). Importantly, AMACR overexpression independently predicted worse disease-specific survival (p=0.0452, RR 1.887). Expression levels of AMACR mRNA and total protein in various cells were comparable. The abundance of AMACR expression increased in tumour cells and was even higher in the metastatic cell line. Conclusions: In primary gallbladder carcinoma, AMACR overexpression was correlated with important prognosticators and independently portended worse outcomes, highlighting the potential prognostic and therapeutic utility of AMACR in gallbladder carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84862826246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862826246&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2011-200489

DO - 10.1136/jclinpath-2011-200489

M3 - Article

C2 - 22267983

AN - SCOPUS:84862826246

VL - 65

SP - 309

EP - 314

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 4

ER -